Christopher Pleyer

5PUBLICATIONS
6CO-AUTHORS
Cellular immunologyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 14, 2022
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.

Christopher Pleyer, Kerry J Laing, Mir A Ali

|Mar 03, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study.

Sanjal Desai, Clifton Mo, Erika M Gaglione

|Aug 19, 2020
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Christopher Pleyer, Xin Tian, Shakuntala Rampertaap

|Jun 09, 2020
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.

Christopher Pleyer, Clare Sun, Sanjal Desai

|May 17, 2018
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Christopher Pleyer, Adrian Wiestner, Clare Sun

Pageof 1

Frequent Collaborators

4 joint publications

Clare Sun

1 joint publications

Erika Gaglione

1 joint publications

Sanjal Desai

1 joint publications

Inhye E Ahn